text:
189 members
253 members
Welcome to the HEP community. You may be interested in the INFRARED THERMOGRAPHY USERS GROUP:
Best regards,
Hi Eric,
Welcome to Home Energy Pros! Feel free to join the conversation in the Forum and Groups. And share your energy efficiency photos, videos and
upcoming events. If you're blogging about home performance, this is the
place for you!
Don't forget to add your location on our Member Map!
Diane, HEP Moderator
© 2017 Created by Lawrence Berkeley National Laboratory. Powered by


text:
ANNAPOLIS, MD - Veteran midfielders Kyle Dixon and Steven Brooks led the way as the Chesapeake Bayhawks earned a huge road victory, beating the Denver Outlaws 18-16 on Saturday night at Sports Authority Field.
Dixon fired in a pair of 2-point goals totaling seven points while Brooks scored the game-tying and winning goals for five points for Chesapeake, which improved its record to 4-1 and moved into a first place tie with Boston.
"This was a real character win and I'm very proud of our players," Chesapeake head coach
Dave Cottle said. "Hopefully, a big road win like this will make our team tighter."
Chesapeake trailed 15-13 and had been shut out for the entire fourth quarter when Brooks cleared the ball across midfield, stopped just outside the 2-point arc and rifled a rocket shot past Denver goalie
Jesse Schwartzman to tie the score with 5:49 remaining in the game.
"That was a huge swing for us and definitely built momentum for the stretch run," Brooks said of the clutch 2-pointer.
Short stick defensive midfielder
John Orsen then gave Chesapeake the lead when he finished a fast break with a left-handed crank shot from just inside the 2-point arc. It was Orsen's first goal of the season and gave the Bayhawks a 16-15 lead with 2:54 to go.
Denver won the ensuing face-off and head coach
Jim Stagnitta called timeout to set up a play that worked to perfection with rookie
Mark Matthews finding fellow attackman
Jordan McBride open on the doorstep for a quick-stick goal that tied the game at 16.
Brooks answered just 34 seconds later with a phenomenal goal that would prove the game-winner. The fifth-year professional out of Syracuse dodged down the left alley and stunned Schwartzman with an amazing wraparound shot that gave the visitors a 17-16 lead with 2:20 left.
"I just kind of winged that one. I came down on a low angle and knew I couldn't get it past Jesse with a regular shot because he plays that pipe so tight," Brooks said. "My only option was to go behind-the-back and I was lucky it went int."
Chesapeake won the ensuing face-off and attackman
Ben Rubeor took a feed from Dixon and fired in an insurance goal that sealed the gutsy win. Rubeor finished with two goals and extended his scoring streak to 21 games as the Bayhawks improved to 3-0 on the road this season.
Denver, led by All-Star attackman
Brendan Mundorf, came out on fire and built a commanding 8-3 lead after one quarter. Mundorf had a goal and two assists while Matthews, a left-hander out of the University of Denver who was making his pro debut, scored two goals during the onslaught.
However, the Bayhawks refused to fold and outscored the Outlaws 6-1 to start the second quarter. Dixon unleashed his second 2-pointer and scored another goal while rookies
Brent Adams (Fairfield) and
Matt Mackrides (Penn State) netted their first career goals during the rally.
Michael Kimmel scored unassisted to complete the comeback and tie the score at nine with just over six minutes elapsed in the second period. It was a slugfest the rest of the way with neither team leading by more than two goals over the final 2 ½ quarters.
"We dug deep and didn't quit. This is the kind of win that really builds character and team camaraderie," Brooks said.
Drew Westervelt returned to the city where he played for five seasons and contributed a goal and two assists. After allowing eight goals and making just three saves in the first quarter, goalie
Kip Turner regrouped and finished with 10 stops for the Bayhawks.
"Tonight's win was all about our veteran presence. We fell behind to a very good team on the road and our veteran players just kept fighting," Cottle said. "Kip Turner is an example of a veteran who never gets rattled. He gives up eight goals in the first quarter and doesn't flinch. He battled and made some unbelievable saves."
Adam Randcaptured 19 of 34 faceoffs for Chesapeake, which plays its next three games at home beginning on Saturday, June 9
th against the expansion Charlotte Hounds. Kimmel finished with a goal and an assist as the Bayhawks had a balanced offense that featured 10 different goal scorers.
Mundorf finished with a game-high eight points on three goals and five assists while McBride and Matthews both totaled five points on four goals and two assists. Schwartzman was spectacular at times in making 17 saves for Denver (3-2).
The Bayhawks return home on Saturday, June 9
th to battle the Charlotte Hounds. Tickets can be purchased online at
www.thebayhawks.comor over the phone by calling the box office 866-99-HAWKS (42957). Reserve your seat today and see the Bayhawks battle at Navy-Marine Corps Memorial Stadium this summer.
For the Bayhawks full schedule go to

subset: commoncrawl


text:
Jean Baptiste Lacroix/WireImage; Richard Young/Startraks
Everyone has a favorite dress that they love to wear over and over again — but to two major events in one week? Heidi Montag hit Kitson to promote her new clothing line Heidiwood in a Chloe dress and matching shoes, only to wear the exact same outfit days later to the White House Correspondents Dinner in D.C. There is definitely nothing wrong with wearing the same outfit twice, but maybe give it a little bit more space? This is clearly becoming a habit for Heidi. Tell us: Would you wear the same outfit twice in one week knowing you'd be photographed both times?


text:
Jarrard & Associates
Jarrard & Associates has been serving the medical device industry since 1990. Our company specializes in the development of real-time microprocessor-based surgical and monitoring instruments and accessories. Combining our business experience with our technical knowledge, we help our clients meet the demands of technological changes and advancements in the medical device industry.
Our Team
Our team is available to help in every phase of the product development process, from the initial idea to production. We work closely with our clients to establish a design approach and ensure that the product is completed in a timely and efficient manner.
We have particular expertise in the areas of finite element modeling, RF ablation, feasibility studies, technology assessment, and new product development. We have been performing finite element modeling since 2000 and using COMSOL Multiphysics exclusively since 2005. We specialize in modeling the interaction of medical devices with human tissue and have particular expertise in modeling devices that deliver therapeutic energy, including RF, microwave, and cryogenics.
Areas of Specialization
We specialize in the following areas:
- Electromagnetics
- DC, AC, RF, and microwave
- Static and time dependent
- Temperature-dependent material properties
- PID controlled applied voltage/current/power
- RF and microwave bioheating
- Contact resistance
- Electrical circuits
- Heat transfer
- Bioheat treatment and thermal therapy
- Conjugate heat transfer
- Phase change
- Heat transport
Fluid dynamics
- Medical/biophysical applications, such as flow in blood vessels and airways
Address and Contact Information
Jarrard & Associates
Phone: 303-332-8498
Website: www.jjarrard.com
Email: firstname.lastname@example.com


text:
Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet`s Disease (INCYTOB) (INCYTOB)
Recruitment status was: Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
|Behcet's Disease Panuveitis Posterior Uveitis Retinal Vasculitis
|Drug: Cyclosporin A Drug: Interferon-alpha2a
|Phase 3
|Study Type:
|Study Design:
|Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:
|Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet`s Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB)
- Improvement of disease activity and preservation of visual acuity (monthly, at one and 2 years) [ Time Frame: 2 years ]
- Time to improvement and remission [ Time Frame: 2 years ]
- Laboratory values for inflammatory activity (monthly) [ Time Frame: 2 years ]
- Number of switches from one treatment to the other [ Time Frame: 2 years ]
- Quality of life for patients with low vision (monthly) [ Time Frame: 2 years ]
- Number of ocular and non-ocular relapses (1 year, 2 years) [ Time Frame: 2 years ]
- Duration of the treatment-free period (second year) [ Time Frame: 2 years ]
|Estimated Enrollment:
|Study Start Date:
|November 2004
|Estimated Study Completion Date:
|December 2012
|Estimated Primary Completion Date:
|September 2012 (Final data collection date for primary outcome measure)
|Assigned Interventions
Active Comparator: A
Cyclosporin A
Drug: Cyclosporin A
3 mg/kg bw, augmented to 5 mg if necessary and combined with prednisolone. Adapted to serum levels
Experimental: B
Drug: Interferon-alpha2a
3-6 million iU per day sc., augmented to up to 9 if necessary, later reduced (according to clinical response) to 3 x 3 million iU /week.
Detailed Description:
Behcet`s disease is a multisystem vasculitis often involving ocular (retinal) blood vessels (in 70% of all cases). This form of uveitis or retinal vasculitis still leads to blindness in 25 to 50% of the patients irrespective of immunosuppressive treatment.
The aim of the study is to evaluate if Interferon-alpha2a is superior to the present standard treatment (cyclosporin A (CSA)) for severe ocular (panuveitis, posterior uveitis, retinal vasculitis) Behçet`s Disease (BD) and significantly improves visual prognosis and quality of health and life of the patients with ocular BD and is acting more rapidly than standard treatment. Furthermore, we want to evaluate if IFN-α induces long term remissions of ocular BD which can be maintained without further medical treatment.
The patients are randomised into two treatment groups (IFN/CSA) and treated for one year according to an algorithm which adapts dosages to clinical course. A crossover from one treatment arm to the other is planned in case of inefficacy.
|Ages Eligible for Study:
|18 Years to 75 Years (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Inclusion Criteria:
- Behçet`s disease fulfilling the International Study Group Criteria with active pan- or posterior uveitis (according to the posterior uveitis scoring system) or retinal vasculitis and active disease according to the Behcet`s Disease activity scoring system.
Exclusion Criteria:
- Previous treatment with interferon-α or cyclosporin A
- Pregnancy, breast feeding women, malignancy
- Renal impairment (creatinine > 1.5 mg/dl)
- Uncontrolled hypertension or diabetes
- Depression or other psychic disorders(also history of depression)
- History of acute or chronic inflammatory joint or autoimmune disease
- Organ or bone marrow transplant recipient, cardiac failure > NYHAIII
- Acute liver disease with SGPT 2x above normal
- White blood cell count < 3500/mm3
- Platelet count < 100000/mm3
- Hgb < 8.5g/dl
- Body weight <45 kg
- Alcohol abuse or drug abuse
- Mental impairment
- Uncooperative attitude
Please refer to this study by its ClinicalTrials.gov identifier: NCT00167583
|Contact: Ina Koetter, MD
|Contact: Christoph Deuter, MD
|Department of Internal Medicine II and Department of Ophthalmology
|Tuebingen, Germany, D-72076
|Contact: Ina Koetter, MD +49-7071-2985138 email@example.com
|Contact: Christoph Deuter, MD firstname.lastname@example.com
|Principal Investigator: Ina Koetter, MD
|Sub-Investigator: Christoph Deuter, MD
|Sub-Investigator: Manfred Zierhut, MD
|Sub-Investigator: Ilhan Guenaydin, MD
|Principal Investigator:
|Ina Koetter, MD
|Tuebingen University Hospital
Additional Information:
|Responsible Party:
|Prof. Ina Koetter, University Hospital Tuebingen
|ClinicalTrials.gov Identifier:
|NCT00167583 History of Changes
|Other Study ID Numbers:
|Study First Received:
|September 9, 2005
|Last Updated:
|July 26, 2010
Keywords provided by University Hospital Tuebingen:
Ocular Behcet`s disease
Posterior Uveitis
Retinal vasculitis
Cyclosporin A
Additional relevant MeSH terms:
Behcet Syndrome
Uveitis, Posterior
Retinal Vasculitis
Uveal Diseases
Eye Diseases
Vascular Diseases
Cardiovascular Diseases
Mouth Diseases
Stomatognathic Diseases
Uveitis, Anterior
Hereditary Autoinflammatory Diseases
Genetic Diseases, Inborn
Skin Diseases, Genetic
Skin Diseases
Skin Diseases, Vascular
Retinal Diseases
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
ClinicalTrials.gov processed this record on September 21, 2017


text:
10 Beauty Fast-Passes to Total Babedom
Get Katharine Ross' full, fluttery fringe:
1. Start by curling your lashes, but not just at the roots. Instead, working from roots to tips, clamp the curler several times along your lashes, which helps form a natural-looking bend.
2. Brush on two coats of a lengthening mascara, layering it on thicker at your lashes' outer corners for a flirty, cat-eye effect.
3. Wipe off the wand with a tissue, then comb it through your lashes one last time to separate and define them.
Get Cindy Crawford's strong brows:
1. For the most natural look, use a brow pencil — not powder — in a shade that matches the hairs. (The one exception: If you have very fair brows, pick a pencil that's one shade darker.)
2. You only want to fill in the sparse areas of your brows; otherwise, they'll look drawn on. Start by sketching the pencil along — but not above — the top edge of each brow using short, light flicks. Next, fill in just the bald spots, again with short flicks — and then, stop.
3. Sweep a spooley brush through your brows to blend in the pencil and create a soft, flawless finish.
The 50 Most Iconic Beauty Looks of All Time


text:
New 3D adventure from Steven Spielberg and Peter Jackson...
To insure your action figure collection, get in touch with our sponsor Collectibles Insurance.
For a great selection of film, comic and TV action figures and collectibles, check out BigBadToyStore.com, BriansToys.com, ToyWiz.com, ToyDorks.com, MonkeyDepot.com, and Sekaido.com.
For an amazing selection of original sculptures, statues, prints and DVDs be sure to check out ShiflettBrothers.com.
Renown filmmaker Steven Spielberg returns to the director's chair this December with a 3D adventure called The Adventures of Tintin.
The film is being produced by Peter Jackson with Weta Digital on Animation and Visual Effects and Weta Workshop on Conceptual Design. It stars Jamie Bell (Billy Elliot, Defiance) as Tintin, the intrepid young reporter whose relentless pursuit of a good story thrusts him into a world of high adventure, and Daniel Craig (Quantum of Solace, Defiance) as the nefarious Red Rackham.
The Adventures of Tintin opens in theaters December 23rd, 2011.


text:
What's your toddler's personality type?
Knowing this could impact your parenting style more than you realise. more
Babies and young children learn a lot about their world by touching things and putting them into their mouths. They also often have a go at eating things that we think disgusting - dirt, chalk, coffee grounds, ashes - and others that we think may be a health risk - glue, rust, paint chips, cigarette buts.
Usually after a couple of experiments, most children come to the same conclusion as their parents, that these things are yuk to eat! But there are some who persist in eating things that aren't food. This behaviour, called pica, may be a sign that the child has a developmental, behavioural, emotional, nutritional or health problem.
Why some children develop pica is not clearly understood, but experts do agree that it's more likely to happen when children have some type of problem like:
Some children who are developing normally develop a pica habit. But before you can dismiss it as curiosity and something that your child will just grow out of, have her thoroughly checked out by your GP.
While it will probably be a completely normal phase your toddler is going through, it's always best to discourage the eating of non-food items. Pica can lead to some serious health issues such as:
Some young children persist in eating things that are not food even after you try to stop the behaviour. No doubt, your child will grow out of pica but in the meantime, it's important to have her health and development regularly checked by your GP.
Low iron levels can cause pica in some children.
Low zinc levels can cause pica in some children.
This article was written by Ella Walsh for Kidspot. Sources include SA Government's Parenting and Child Health.
This article was created for Kidspot - Australia's parenting resource for toddlers.
Last revised: Wednesday, 11 June 2008
This article contains general information only and is not intended to replace advice from a qualified health professional.


text:
Preventing Acute Renal Failure After Cardiac Surgery in High Risk Patients Using Sodium Bicarbonate Therapy (PARACHUTE)
Recruitment status was: Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
|Kidney Failure, Acute
|Drug: Sodium bicarbonate Drug: Sodium chloride
|Phase 3
|Study Type:
|Study Design:
|Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
|Official Title:
|Preventing Acute Renal Failure After Cardiac Surgery in High Risk Patients Using Sodium Bicarbonate Therapy (PARACHUTE) - Pilot Study
- Increase in serum creatinine of 44 micromol/L or by 25% within the first 3 days after surgery. [ Time Frame: 3 days ]
- Postoperative vasoactive medication, intra-aortic balloon pump, mechanical ventilation, reintubation, reoperation, myocardial infarction, stroke, infection, hypokalemia, dialysis, ICU and hospital length of stay and survival. [ Time Frame: 3 weeks post operative period ]
|Estimated Enrollment:
|Study Start Date:
|May 2006
|Estimated Study Completion Date:
|March 2013
|Estimated Primary Completion Date:
|December 2012 (Final data collection date for primary outcome measure)
|Assigned Interventions
Experimental: Intervention
Three ampoules of 7.5% sodium bicarbonate (89.3 mOsm/ampoule; total 150 ml for three ampoules) added to 750 ml of 5% dextrose in water, given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
Drug: Sodium bicarbonate
Three ampoules of 7.5% sodium bicarbonate (89.3 mOsm/ampoule; total 150 ml for three ampoules) added to 750 ml of 5% dextrose in water, given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
Other Name: NaHCO3
Active Comparator: Control
0.9% sodium chloride given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
Drug: Sodium chloride
0.9% sodium chloride given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
Other Name: saline
Detailed Description:
Acute renal failure (ARF) is an important complication after cardiac surgery that has a prevalence ranging between 5 and 30%. In addition, the impact of chronic kidney disease (CKD) has been well correlated with poorer outcomes after cardiac surgery. These factors have been demonstrated to be associated with increased morbidity, mortality, as well as consuming limited health care resources.
Despite the identification of certain higher risk determinants such as emergency surgery, valvular surgery, preoperative creatinine level, diabetes, increasing age, obesity, and peripheral vascular disease, interventions to decrease postoperative ARF in these patients have been limited. Agents that have been successful in other settings, such as N-acetylcysteine and fenoldopam, have shown no difference in clinical outcomes of ARF when tested in randomized clinical trials in high-risk cardiac surgery patients. Although prophylactic hemodialysis has been shown to be effective for patients with underlying severe kidney disease, this is clearly a resource intensive therapy that may not be practical as a general prophylaxis strategy.
The use of sodium bicarbonate has shown efficacy in reducing the incidence of ARF due to contrast-induced nephropathy in those patients with moderate, stable renal dysfunction. The postulated mechanism of renal protection has been described through the prevention of free radical generation and damage. The generation of a higher renal proximal tubule pH with bicarbonate therapy may slow down the superoxide-generating Haber-Weiss reaction, limiting the formation of free radical oxidants. In addition, sodium bicarbonate may be directly scavenging reactive oxygen species generated from nitric oxide, at a physiologic pH.
If it is presumed that initiation and extension of ischemic renal injury occurs during cardiac surgery via oxidant injury, the use of sodium bicarbonate to disrupt this process could possibly be an effective therapeutic option to prevent ARF.
The objective of this study is to evaluate the renal protective effect of near-isotonic sodium bicarbonate as compared to sodium chloride when given as prophylaxis to patients with chronic kidney disease prior to non-emergent surgery involving the use of cardiopulmonary bypass.
Our hypothesis is that bicarbonate therapy may disrupt ischemia-induced, oxidant-mediated injury and this may prevent the propagation of renal damage. These events may be demonstrated clinically by a reduced incidence of ARF following surgery, decreased requirements for renal replacement therapy after surgery, and improved survival both perioperatively and in a longer-term follow up.
|Ages Eligible for Study:
|18 Years and older (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Inclusion criteria:
- age greater than or equal to 18 years
- elective or urgent CABG +/- valve surgery, or elective or urgent isolated valve surgery
- exposure to cardiopulmonary bypass
- stable kidney disease: less than 25% change in serum creatinine during 3 months before surgery
- Estimated glomerular filtration rate, by Modification of Diet in Renal Disease (MDRD) equation, less than or equal to 60 ml/min/1.73m2
Exclusion criteria:
- emergency CABG, cardiac transplantation, or insertion of VAD
- planned off-pump surgery
- N-acetylcysteine given in last 72 hours prior to operation
- radiocontrast given in last 48 hours prior to operation
- acute renal failure (greater than 25% increase in serum creatinine from preadmission baseline)
- glomerular filtration rate less than 15 ml/min or chronic dialysis
- prior renal transplantation
- enrollment in another research study, with the exception of MUHC study SDR-05-033
- LV ejection fraction less than or equal to 20%
Please refer to this study by its ClinicalTrials.gov identifier: NCT00522756
|Contact: Carole Albert, RN
|(514) 934-1934 ext 34980
|Contact: Ahsan Alam, MD
|(514) 934-1934 ext 31586
|Canada, Quebec
|McGill University Health Centre - Royal Victoria Hospital
|Montreal, Quebec, Canada, H3A1A1
|Principal Investigator: Benoit de Varennes, MD
|Principal Investigator: Ahsan Alam, MD
|Sub-Investigator: Danny Del Duca, MD
|Sub-Investigator: Sameena Iqbal, MD
|Sub-Investigator: Peter Goldberg, MD
|Sub-Investigator: Navdeep Tangri
|Principal Investigator:
|Benoit de Varennes, MD
|McGill University Health Center
|Principal Investigator:
|Ahsan Alam, MD
|McGill University Health Center
|Responsible Party:
|McGill University Health Center
|ClinicalTrials.gov Identifier:
|NCT00522756 History of Changes
|Other Study ID Numbers:
|Study First Received:
|August 29, 2007
|Last Updated:
|October 22, 2012
Keywords provided by McGill University Health Center:
Kidney Failure, Acute
Cardiac Surgical Procedures
Sodium Bicarbonate
Sodium Chloride
Prevention and control
Additional relevant MeSH terms:
Renal Insufficiency
Acute Kidney Injury
Kidney Diseases
Urologic Diseases
ClinicalTrials.gov processed this record on September 21, 2017


text:
The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients
This study has been completed.
Gilead Sciences
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: August 1997
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Detailed Description:
To evaluate the safety and tolerance of topical cidofovir (HPMPC) therapy for condyloma acuminatum in patients with HIV infection. To investigate whether topical HPMPC therapy can induce regression of condyloma acuminatum in patients with HIV infection.
|HIV Infections Condyloma Acuminata
|Drug: Cidofovir
|Phase 1
|Study Type:
|Study Design:
|Primary Purpose: Treatment
|Official Title:
|A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Condyloma Acuminatum in Patients With HIV Infection
Resource links provided by NLM:
MedlinePlus related topics: HIV/AIDS
Drug Information available for: CidofovirU.S. FDA Resources
Further study details as provided by NIH AIDS Clinical Trials Information Service:
|Estimated Enrollment:
Four groups of 10 patients each receive topical HPMPC at 0.3 percent concentration for 5 or 10 days total or 1.0 percent concentration for 5 or 10 days total, followed by 2 weeks of rest. When six patients at a given dose and schedule have completed treatment and follow-up without significant toxicity, subsequent patients are entered at the next higher dose level. Patients are evaluated twice weekly during treatment and once weekly during the rest period. HPMPC may be extended for up to two additional courses in patients who experience no significant toxicity.
|Ages Eligible for Study:
|18 Years and older (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Inclusion Criteria
Concurrent Medication:
- AZT, ddI, ddC, d4T, or 3TC.
- Oral trimethoprim/sulfamethoxazole.
- Aerosolized pentamidine.
- Dapsone.
- Fluconazole.
- Rifabutin.
- Clarithromycin.
Patients must have:
- HIV seropositivity.
- Mean CD4 count >= 100 cells/mm3.
- External anogenital condyloma acuminatum confirmed by biopsy, present for less than 1 year. NOTE:
- Warts on anal, urethral, or vaginal mucosa will not be studied.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Active lesions of genital herpes, other skin wounds, or active inflammatory skin disorders in the same area as warts to be treated.
- Active medical problems sufficient to hinder study compliance.
Concurrent Medication:
- Podofilox or any podophyllum resin preparation.
- Liquid nitrogen treatment.
- Interferon alpha.
- Trichloracetic acid.
- Other treatments, topical or systemic, surgical or ablative, known to have anti-papilloma activity.
- Other investigative drugs (except d4T or 3TC) unless approved by the sponsor.
Patients with the following prior conditions are excluded:
History of untreated syphilis or Bowenoid papulosis.
Prior Medication:
Excluded within 4 weeks prior to study entry:
- Treatment for anogenital warts.
- Immunomodulators (including interferons or systemic corticosteroids).
- Lymphocyte replacement therapy.
- Biologic response modifiers. Substance abuse.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002327
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002327
|United States, California
|East Bay AIDS Ctr
|Berkeley, California, United States, 94705
|Univ California San Francisco
|San Francisco, California, United States, 941430316
|United States, Colorado
|City and County of Denver / Dept of Health & Hosps
|Denver, Colorado, United States, 802044507
|United States, New York
|Bronx-Lebanon Hosp Ctr
|Bronx, New York, United States, 10453
|Univ of Rochester Med Ctr
|Rochester, New York, United States, 14642
|United States, Texas
|Houston Clinical Research Network
|Houston, Texas, United States, 77006
|Dr Brad Bowden
|Houston, Texas, United States, 77027
|Dr Stephen Tyring
|Nassau Bay, Texas, United States, 77058
|United States, Utah
|Univ of Utah School of Medicine
|Salt Lake City, Utah, United States, 84132
|United States, Washington
|Univ of Washington / Viral Disease Clinic
|Seattle, Washington, United States, 98122
|Pacific Med Ctr
|Seattle, Washington, United States, 98144
Sponsors and Collaborators
Gilead Sciences
More Information
Keywords provided by NIH AIDS Clinical Trials Information Service:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 25, 2017
Douglas J, Corey L, Tyring S, Kriesel J, Bowden B, Crosby D, Berger T, Conant M, McGuire B, Jaffe HS. A phase I/II study of cidofovir topical gel for refractory condyloma acuminatum in patients with HIV infection. Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:126 (abstract no 334)
|ClinicalTrials.gov Identifier:
|NCT00002327 History of Changes
|Other Study ID Numbers:
|Study First Received:
|November 2, 1999
|Last Updated:
|June 23, 2005
Keywords provided by NIH AIDS Clinical Trials Information Service:
AIDS-Related Opportunistic Infections
Acquired Immunodeficiency Syndrome
AIDS-Related Complex
Antiviral Agents
Condylomata Acuminata
Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Antiviral Agents
Anti-Infective Agents
ClinicalTrials.gov processed this record on September 25, 2017


text:
Fuld runs, then appears in Minor League game
PORT CHARLOTTE, Fla. -- Sam Fuld went through an intense outfield workout involving a lot of running Thursday morning, and after coming out of it without any issues with his right hamstring, he appeared in a Minor League game.
"Feels pretty good," Fuld said after his morning workout.
"Everything went fine," Fuld said after he made four plate appearances, walking once, but did not play the field.
Fuld has been out since experiencing tightness in his right hamstring in a March 3 game. Given that much of what Fuld does on a baseball field is predicated by being able to use his legs, the Rays have taken a cautious approach with the outfielder.
Rays manager Joe Maddon seems optimistic about Fuld's progress, and the outfielder is expected back by Opening Day.
Bill Chastain is a reporter for MLB.com. This story was not subject to the approval of Major League Baseball or its clubs.


text:
This game was classified by the community with the following category scores - Violence=0/3, Sex=0/3, Mature Content=0/3. MegaCity is an original and fun 'one-more-go' style city building puzzle game. Easy to learn, hard to master gameplay which requires strategy, logic and luck. Place buildings in the queue to earn points, but watch out, nobody wants to live next to a landfill or industrial estate! Megacity is a game of planning ahead to squeeze the most points of out your citizens by clever town planning.
Buy Xbox content on Xbox.com. Your Xbox 360 console will automatically download the content next time you turn it on and connect to Xbox Live.Learn More


text:
The Montag Store
At the Montag Store we sell food, rent out DVDs, and make coffee. Some of the food that we sell includes bagels, sandwiches, chips, candy, soda, Naked Juice, cookies, popcorn, Red Bull, wraps, string cheese, milk, fresh bread, soup, and much more. We are also constantly updating our video collection, which can be rented out at the rate of $1 for one dvd for one night. Not a bad deal right?


text:
Collaborative Projects
Send by emailPDF version
The Special Collections Research Center has worked with other organization to produce a number of online resources.
Irish Literary Collections Portal
Access to finding aids of over 100 of North America's Irish literary manuscript collection.
Modernist Journals for Cover-to-Cover Project
Lists the holdings of the top Modernist Journals at several institutions, including Morris Library.
Lawrence Durrell's Personal Library
Cataloged on LibraryThing as part of the Legacy Libraries project.


text: OverviewBack to top Biggs & Featherbelle - Soothing Soak Oatmeal, Buttermilk & Chamomile with Lavender Essential Oil - 9 oz. Item# :113364UPC# :857417001232 Brand:Biggs & Featherbelle Size/Form:9 oz. Ship Weight:0.70 Biggs & Featherbelle Soothing Soak Oatmeal, Buttermilk & Chamomile with Lavender Essential Oil - 9 oz. Biggs & Featherbelle Soothing Soak Oatmeal, Buttermilk & Chamomile with Lavender Essential Oil. Biggs & Featherbelle baths soaks are unique recipes created with nourishing salts, herbs, buttermilk & essential oils. These bath soaks were created to soak away your problems and add some "me-time" to your daily routine. Whether you need to soak your achy muscles, relax your mind, soothe itchy skin or just feel beautiful then we have created a bath soak for you. Every ingredient is purposeful and free from synthetic fragrances, dyes and additives. Biggs & Featherbelle Soothing Soak : Colloidal Oatmeal Moisturizes & Protects Skin Buttermilk Moisturizes & Soothes Skin Oat Straw Reduces Itchiness Chamomile & Lavender Soothe Skin Biggs & Featherbelle Soaks Are: Handmade Natural No Synthetics Frequently Asked Questions Who are Biggs & Featherbelle?Biggs & Featherbelle are somewhat fictional. Biggs (formerly named Bubba) is a character inspired from their cat named Diesel. Featherbelle is a fusion of Kelly & Kasey. Biggs & Featherbelle represent a broad spectrum of people from manly tough to girly sweet. The characters were developed and illustrated by their friend Brian Dugan (who prefers to stay behind the scenes). What is Sodium Hydroxide?Sodium Hydroxide is lye, an essential ingredient in soap making. Lye and oils react together to create soap therefore no lye is in the final product. In their recipes the amount of oil is always greater than the needed lye so that their bars are moisturizing and gentle to the skin. How do you make soap?Mixing oils and a lye water solution makes soap. Once the oils and lye are combined together, after vigorous stirring, the mixture thickens and is poured into molds. The molds are covered for 24 hours to allow the saponification process to occur. After the 24-hour period, the soap is taken out and cut into bars. The bars must cure for three to four weeks (for the entire chemical reaction to finalize) before use. Can the soaps be used on face and body?Yes! Every one of their soaps is gentle enough for the face and cleansing enough for the body. Handle Bar, Fixins Bar, Momma Bar, and Bar-tender are especially good for the face. Are your products vegan?Many of their products are vegan and all are vegetarian. The vegan products are as follows: Soaps Bark Fixins Bar Barbados Handle Bar Bar-tender Beach Bar Barlesque Bar-lamint Bar-chouli Lemon Bar Tequila Bar Bardot Koala Bar Polar Bar Soaks & Body Scrubs Bath Soaks Muscle Soak Mind Soak Flower Soak Lip Balms Both use beeswax, sorry. What products are you making in the future?They have many ideas brewing in their heads but definitely on their list are liquid soaps, body and face lotions and healing balms/salves. Farther in the future they would love to explore making shampoo, conditioner, and deodorants. Do your products "go bad" after a period of time?Their products are preserved with Vitamin E. They will keep fresh for up to 2 years although after 1 year you may notice the aroma starts to fade. How long does a bar of soap last?A bar of soap can last several weeks if properly stored. Natural, handmade soap is softer than commercial detergent bars and needs to be kept in a dry spot when not in use. Having a soap dish with good drainage is key; soap left standing in water or under a leaky showerhead will melt fast. How do you color and scent your products?They let Mother Nature do the work. All of their products are fragranced only with essential oils (which have many therapeutic benefits). The colors are derived from plants, herbs, and vegetable oils. About Biggs & Featherbelle Biggs & FeatherbelleBiggs & Featherbelle is a health conscious company that promotes the healing elements of Mother Nature by creating body care products free from synthetic fragrances, dyes and additives. Quality ingredients and research are infused in every handmade Biggs & Featherbelle product. Enjoy! Biggs & Featherbelle Story… The birth of Biggs & Featherbelle:Sisters Kelly and Kasey Evick created Biggs & Featherbelle in January 2003. A magazine article inspired the pair to make 'melt and pour' glycerin soaps as Christmas presents. With backgrounds in the Fine Arts and Fashion, the two had fun creating unique recipes, packaging and clever names for each item. The gifts were a big hit. Their family had always been proponents of alternative healing practices and consumers of natural beauty products. So, it seemed fitting to continue exploring the benefits of botanicals. The innocent investigation soon turned to obsession. The sisters quit their day jobs and devoted every hour to research and invention, striving to create the products they couldn't find on the shelves. Fueled by encouragement from friends and family, the word spread to local festivals, then regional fairs and eventually in stores throughout the U.S. Today, armed with the collected experience and knowledge of essential oils and other critical ingredients, the mission is to create products with a purpose. Paying close attention to packaging and presentation of the company, the focus is on specific solutions for all skin types. Biggs & Featherbelle is committed to providing products that everyone enjoys and benefits from. So who are Biggs & Featherbelle?Biggs & Featherbelle are somewhat fictional. Biggs (formerly Bubba) is a character inspired from our kitty cat named Diesel. Featherbelle is a fusion of Kelly & Kasey. Biggs & Featherbelle represent a broad spectrum of people from manly tough to girly sweet. The characters were developed and illustrated by our friend Brian Dugan (who prefers to stay behind the scenes).


text:
Star Wars Saga To Continue in 2015...
Pixar. Marvel. Star Wars?! In shocking breaking news, Disney has announced the acquisition of Lucasfilm in a deal valued at $4.05 billion. As new owners of George Lucas' entertainment empire, Disney has revealed plans to continue the Star Wars Saga beyond Return of the Jedi, with Episode VII targeted for release in 2015. Disney CEO Bob Iger said Lucasfilm had already developed an extensive story line on the next trilogy and Episode VII was now in early-stage development. Lucas will serve as creative consultant in the new movies.
The deal also includes high-tech production companies Industrial Light & Magic and Skywalker Sound, as well as rights to the Indiana Jones franchise.
Let the speculation of who will play the new Luke, Han and Leia begin...
To insure your action figure collection, get in touch with Collectibles Insurance, the official insurance company of the Figures.com network. Say "Figures.com" to get 5% off your first term premiums.
To buy action figures, take a look at BigBadToyStore.com, Toynk.com, PastGenerationToys.com, BriansToys.com, ToyWiz.com, and MonkeyDepot.com.
For action figures, statues and sculptures, go to CSMooreStudio.com.


text:
FREMONT — Three people, including a 4-year-old girl who suffered major injuries, were hurt in an early Monday head-on crash in the Cameron Hills neighborhood and police suspect both drivers were drinking.
Emergency crews responded at 12:15 a.m. to Osgood Road near Blacow Road for a report of a two-car wreck, said police spokeswoman Geneva Bosques.
A 33-year-old Fremont woman was driving a silver Honda Civic south on Osgood Road when she veered into the northbound lanes and slammed into a silver Toyota Camry, police said.
The woman was about one block from her home when the crash took place and had her 4-year-old daughter buckled into a car seat, but police said it was not anchored to the back seat.
The girl suffered life-threatening injuries and was taken to Children's Hospital Oakland, where she remained in critical condition on Monday, Bosques said. Her mother was transported to a hospital in critical condition but was later upgraded to stable condition, Bosques said.
Officers smelled alcohol on the woman at the scene, Bosques said. As of Monday evening, the woman had not been arrested pending toxicology results, Bosques said.
The driver of the Camry, a 30-year-old Fremont man, suffered minor injuries to his legs and was taken to a hospital, but later released and cited for drunken driving. The man told officers that he had been drinking alcohol before he drove, Bosques said.
A witness told police the woman was driving about 50 to 60 mph before the crash, he said.
The roadway was shut down for several hours but reopened about 6:45 a.m.
Anyone with information about the crash is asked to contact Fremont police at email@example.com or 510-790-6900. Anonymous tips can be left at www.fremontpolice.org/tip.
Contact Natalie Neysa Alund at 510-293-2469. Follow her at Twitter.com/nataliealund.


text:
Find Materials
Patents for Inventions
Last modified: June 26, 2015
Patents - Invention Search
Please Note
While we will gladly assist you with your search, we cannot perform searches or dispense legal information!
7 Steps of an Invention Search:
Identify the key concepts of your invention.
Remember inventions are classified by how they work, rather than their intended use.
Find the class/subclass numbers that best describe your invention by using the Index to U.S. Patent Classifications.
All patents are arranged by class/subclass and this will allow you to view all patents that work in a similar fashion.
View the definitions for the class/subclass you have identified using the Manual of Classification. (Type your class/subclass, select Class Definition then Submit).
This will help you find related classes and subclasses and determine cross-referenced or incorrect classifications.
Look at the abstract and bibliographic information for the patents in the classifications you have identified.
Use this to determine if you've chosen an appropriate classification. Make note of the patent numbers for inventions that are similar to your idea.
Review the complete text and drawings of the related patents and published applications to determine differences between your invention and those that already exist.
Search the Official Gazette and Patent Full-Text Database to ensure no recently posted applications match your invention.
Consider filing a patent application if you haven't found a patent that's the same as your invention.
Content adapted from 7-Step U.S. Patent Search Strategy (USPTO).
Last modified: June 25, 2015
Patents - What is a Patent?
Please Note
While we will gladly assist you with your search, we cannot perform searches or dispense legal information!
What is a Patent?
A patent is a right of ownership granted to a person by the government to exclude others from making or selling the claimed invention for a period of twenty years. There are three main types of patents:
- Utility - granted for the function of something that is mechanical, electrical, chemical, compositional, or any combination of these.
- Design - granted solely on the look or appearance of something.
- Plant - granted for unique, asexually reproduced plants.
Examples of things that may be patented:
Examples of things that may NOT be patented
Manufactured Products
Composition of matter (e.g. pharmaceuticals)
Processes (mechanical or practical, but not thought)
Asexually reproduced plants
Mathematical Functions
Laws of nature
Scientific Principle
Last modified: March 5, 2012
Patents - International Patents
Please Note
While we will gladly assist you with your search, we cannot perform searches or dispense legal information!
Search for Patents Internationally
Worldwide | North America | Europe
Worldwide Sites
World Intellectual Property Organization (WIPO)
STN International
Provides global access to published research, journal literature, patents, structures, sequences, properties, and other data.
British Library - Help for Researchers - Patents
Comprehensive range of web pages on patents, trademarks, and designs; covers intellectual property documentation worldwide.
China, State Intellectual Property Office of the P.R.C. (SIPO)
East Asian Patent Information by EPO
The federal government agency responsible for granting rights in patents, trademarks and designs.
The official site for member states of the EPO. Provides searching and viewing of issued patents and published patent applications. European patents may be published in French, German or English. (Claims are published in all three languages.)
More than 70 million patent documents worldwide, containing information about inventions and developments from 1836 to today.
EPO - European Patent Register
All publicly available information on European patent applications as they pass through the grant procedure, including oppositions, patent attorney/EPO correspondence, and more.
North America
Canadian Intellectual Property Office - Patents Database
This searchable database contains full text of patents issued or publicly-registered after August 15, 1978. It also contains images and brief details for patents from 1920-present and abstracts from 1978-present. The free database of Canadian patents and laid-open patent applications has been made available by Canadian Intellectual Property Office (CIPO).
United States Patent and Trademark Office (USPTO)
Last modified: March 28, 2016
Patents - U.S. Patents
Please Note
While we will gladly assist you with your search, we cannot perform searches or dispense legal information!
Issued U.S. Patents
The specification and accompanying drawings of all patents issued by the U.S. Patent and Trademark Office (USPTO) are available online. New patents are issued and published online every Tuesday.
PatFT - Patent Full-Text and Full-Page Image Databases
Full-page TIFF image (searching only available by patent number, issue date and class/subclass)
Full-text searching of html version of patent (full-page TIFF image with any accompanying images also available)
USPTO Patent Full-Text Database records containing only the patent number and the word "withdrawn" have been added for all withdrawn patent numbers. No further information is available from the USPTO website for these patents. Changes to patent documents contained in Certificates of Correction and Re-examinations Certificates are not included in the searchable full text of the patent databases, but are available as additional full-page images at the end of each patent's linked full-page images.
Published Applications (Disclosure Document)
Patent applications are generally published 18 months after the earliest priority date of the application. Patent applications are published online every Thursday.
A Disclosure Document is not a patent application, and the date of its receipt in the USPTO will not become the effective filing date of any patent application subsequently filed. A Disclosure Document will be retained for two years, and then be destroyed unless it is referred to in a separate letter in a related patent application filed within those two years.
AppFT - Patent Application Full-Text And Image Database
March 15, 2001 - present
Full-text searching of published patent applications with any accompanying images or diagrams
Viewing Patent Full-Page Images (TIFF Files)
A TIFF image Viewers for Patent Images is required to view the scanned, full-page images for each patent in the database. All computers in the UA Main and Science Libraries have this software installed. For information on PDF conversion services for patents, check under the Further Research section.
USPTO Websites
U.S. Patent And Trademark Office (USPTO)
Index to the U.S. Patent Classification (USPC) System
Classification Main Menu
Numerical listing of the patent classification schema. It gives the classification definitions and shows interrelationships between classes.
Official Gazette for Patents (USPTO)
The Official Gazette for Patents allows you to browse through the issued patents for the week. It can be browsed by classification or type of patent, for example by utility, design, and plant. Specific patents can be accessed by class/subclass or patentee name. The USPTO website hosts only the most recent 52 weeks of the Official Gazette for Patents. Older issues are maintained by Reed Tech IP Services.
Micro- film 4444 Science Microforms v.1-v.1254 no.1262 (1872-Jan.-Sept. 2002)
Patent Search Web Resources
A quick guide to patent research (University of Michigan)
7-Step U.S. Patent Search Strategy Guide [PDF] (Patent and Trademark Resource Center Program)
How to Conduct a Preliminary U.S. Patent Search video (USPTO)
Patents (University of Central Florida Libraries)
Google Patent
Google Patent Search covers the entire collection of patents made available by the USPTO from patents issued in the 1790s through present. Search patent number works better than full-text search. Note that Google Patents Search does not include patent applications or international patents. Advanced patent searching is still going to require using the USPTO database and other resources for more precise patent searching.
Last modified: September 21, 2017
Patents - Further Research
Please NoteWhile we will gladly assist you with your search, we cannot perform searches or dispense legal information!
Further Research
PDF Conversion
There are many services offering free or fee-based conversion of patent documents into PDF files. This is a small selection of options.
U.S. patents; TIFF or PDF format; advanced search capabilities; free
U.S. patents; PDF format; free
Library Research Data
The Lens
Formerly called Patent Lens, this site includes a number of different datasets.
LexisNexis Academic Guide
Includes general topic news, as well as company, industry, market, government, and political news. Coverage also includes: country and state profiles, law reviews, federal case law, medical and health topics, and accounting, auditing and tax information, company profiles, and financials (public and private).
Ei Compendex
Citations and abstracts to articles from over 5,000 journals, conference proceedings, and technical reports. EI Compendex provides comprehensive interdisciplinary coverage of all major areas of engineering, applied science, and technology.
Science Citation Index (included in Web of Science)
Index to core journal articles and cited references in science and technology. Includes some abstracts. Science Citation Index (SCI) Expanded is part of the Web of Science database collection. It indexes over 6,650 major journals across 150 scientific disciplines in science, medicine and technology from 1900 to the present. To search only in Science Citation Index, select the Change Limits and Settings link in the lower half of the search page and deselect the Social Sciences Citation Index and the Arts & Humanities Citation Index.
SciFinder is a database that provides access to the following:
- Chemical Abstracts - Over 15 million abstracts of chemistry-related journal articles, patents, conference proceedings, dissertations, and technical reports.
- CASREACT - Information on synthetic organic research, including organometallics, natural products, and biocatalyzed reactions.
- CAS Registry - A database of more than 22 million chemical substances.
- CHEMCATS - Commercially available chemicals from more than 400 suppliers.
- CHEMLIST - Key domestic and international regulatory information.
- MEDLINE - Medline is the National Library of Medicine's premier bibliographic database of international biomedical literature, providing comprehensive information on every aspect of medicine, biomedical research and health care.
With SciFinder, you can find literature relevant to a topic of interest or written by a specific author. You can also explore chemical substances by chemical name, chemical structure and substructure, chemical reactions, formulas, or CAS Registry Numbers.
Note: SciFinder is only available to University of Arizona affiliates with a valid UA NetID. Registration with SciFinder is required to use it. For more information, see the SciFinder page from Chemical Abstracts Service.
Materials Research Database
All aspects of materials science are provided in this collection of databases, which includes Advanced Polymers Abstracts, Aluminium Industry Abstracts, Ceramic Abstracts/World Ceramics Abstracts, Composites Industry Abstracts, Copper Data Center Database, Corrosion Abstracts, Engineered Materials Abstracts, Materials Business File, METADEX, and WELDASEARCH.
Contents include international literature on ferrous and non-ferrous metals, polymers, ceramics, plastics and composite materials, plus practices and commercial developments in materials science.
World literature of physics, astronomy and astrophysics, optics and optoelectronics, electrical engineering, electronics, computers, and computing technology.
Library Books
How to Make Patent Drawings: A "Patent It Yourself Companion" (ebook)
The Inventor's Notebook : A "Patent It Yourself" Companion
Patent it Yourself, 15th ed., 2011
Patent It Yourself, 12th ed., 2006 (ebook)
Patent it Yourself, 8th ed., 2000
Dictionaries & Glossaries
Glossary of Thomson Scientific Terminology
Glossary of Patent Terminology
by Organisation for Economic Co-operation and Development
Patent Glossary
by The Minerals, Metals & Materials Society
USPTO Web Sites
U.S. Patent And Trademark Office (USPTO)
Index to the United States Patent Classification (USPC) System
Alphabetical listing of words or terms that refer to specific classes and subclasses used to categorize patents
Numerical listing of the patent classification schema. It gives the classification definitions and shows interrelationships between classes.
Filing a Patent Application
Tutorial, EFS-Web "Sandbox" - Try Before You File (USPTO)
Guide to Filing A Non-Provisional (Utility) Patent Application
Forms - printable & fillable
Looking for a Patent Attorney
USPTO Patent Attorney / Agent Search
Contains contact information for attorneys and agents with licenses to practice before the U.S. Patent and Trademark Office.
Other Web Resources
America's Inventor Online Magazine
American Patent and Trademark Law Center
BitLaw: A Resource on Technology Law
Inventors Association of Arizona (IAA)
National Congress of Inventor Organizations (NCIO)
National Inventors - Hall of Fame
Nolo Patent, Copyright & Trademark Center
Patent Information Users Group
The Patent Room
Focused on early design and illustration, the site features patent drawings of the 20s, 30s, 40s and 50s.
Univeristy of Maine Library: Patent and Trademark
World Intellectual Property Organization (WIPO)
Humorous Patent Sites
Last modified: September 21, 2017


text:
Williams "L" Series Concealed Floor Console Fan Coil, Left Piping, 115V, 5 Coil Rows (3 CW 2 HW) - 600 CFM, 53,080 BTU
A Floor-mounted model for concealed or exposed applications, the Williams Vertical Series offers the right standard and optional equipment for your application. The slim, compact design of the Vertical Basic (LV-B) fan coil is intended for furred-in applications with a field-fabricated, custom enclosure. Housed in a heavy-gauge galvanized steel cabinet, insulated with 1/2" thick neoprene coated fiberglass, this reliable fan coil is ideal where any through-the-wall installation is desired.Williams LV006W4B321L00 Concealed Floor Console Fan Coil Features:
- Two or Four-pipe hydronic heating and/or cooling. Four-pipe system may be converted to a two-pipe system by capping off one set of pipes. Manual air-vents on water coils.
- Coils are 1/2" OD copper tubes with aluminum fins (12 FPI) with right-hand connection and tested underwater at 350 PSI with a 300 PSI working pressure.
- Drain pan is a black epoxy, powder-coat finished, insulated with 1/4" elastomeric insulation and has a bottom drain connection.
- Three-speed, 115V or 208V/1/60Hz PSC motor with quick-connect plug wired to a junction box.
- Motors are factory-wired and terminated in a junction box for single-point power supply.
- Easily accessible, removable front-access panel.
- One-inch fiberglass, throwaway filter accessible by simply removing the return-air grille.
- 100% factory, leak and performance tested.
- 1 Year


text:
The Australian dollar has hit another one week high as concerns about Russia ease and after another batch of weak US economic data.
At 1700 AEST on Friday, the local unit was trading at 93.27 US cents, up from 92.99 cents on Thursday.
Late on Friday, the currency peaked at 93.37 US cents, its highest level since August 7.
Weekly claims for US unemployment benefits rose by 21,000 to a seasonally-adjusted 311,000, which has helped keep the Aussie above 93 US cents.
RBC senior currency strategist Sue Trinh said the Russian president's more conciliatory tone over Ukraine has encouraged traders to move back into riskier assets such and stocks and the Australian dollar.
"Overall, risk sentiment has improved, in line with slightly positive geopolitical developments," she said.
"President Vladimir Putin said Russia would stand up for itself but not at the cost of confrontation with the outside world."
FxPro chief economist Simon Smith said the Australian dollar has also been rising against a weaker Japanese yen, which has helped prevent the Aussie falling against most currencies.
"We've seen the Australian dollar move higher nearly every day against the yen this week, reversing the sharp fall seen Friday of last week."
Mr Smith said markets will be focused on a meeting of European Union foreign ministers, who will be discussing recent turmoil in Iraq and Ukraine.
At 1700 AEST, the Australian dollar was at 95.65 Japanese yen, up from Thursday's close of 95.30 yen, and at 69.78 euro cents, up from 69.61 euro cents.
Meanwhile, Australian bonds traded in a narrow range.
Westpac senior market strategist Damien McColough said the market had paused after strong sessions earlier in the week, and would be watching the release of US industrial and consumer confidence data on Friday night.
However events affecting the European market would be more important in determining the direction of the market, he said.
"We always look at the US ... but in some ways I think it's going to be led by European geopolitical (events)," he said.
"I don't think (the US) is really going to change the general trend in global markets.
At 1630 AEST on Friday, the September 2014 10-year bond futures contract was trading unchanged at 96.620 (implying a yield of 3.380 per cent).
The September 2014 three-year bond futures contract was at 97.400 (2.600 per cent), down from 97.420 (2.580 per cent) on Thursday.


text:
SALLY Firth, 47, who has been to see Les Miserables on stage an incredible 958 times says the new film of the show is 'absolutely brilliant.'
But Sally, of King's Stanley, near Stonehouse, says she doubts she will get the bug for the film in the same way as she has for the stage musical.
She saw it last Monday, January 14 at the Apollo in Stroud.
"I might go and see it just once more so I can take a better look at the people in the background - a lot of them are from the West End show," she said.
"But I'm not a film buff and I doubt I shall go again after that."
However, her mum Diana was not as impressed by the new film, starring Hugh Jackman and Russell Crowe.
"I didn't like it," said Diana. "It was a big disappointment to me."
Sally, who reckons she has seen Les Miserables more times than anyone on earth, said: "I thought the film was absolutely brilliant and I'm sure it'll be winning a few Oscars.
"The film has been made so that the story is much easier to understand than the stage version.
"I know people who have not been sure what is going on at all on stage but the film makes it all very clear.
"Hugh Jackman was very good, just as I expected, and I was very pleasantly surprised with Russell Crowe.
"Mum liked Anne Hathaway best and she certainly was very good."
The last time Sally went to a stage production of Les Mis was last month, just three days before Christmas.
Sally is so obsessed with seeing every possible performance of the show that she has already spent well over £50,000 on the 'hobby.'
"I just never tire of it. But I'm not the only one - there are an awful lot of people these days who keep going back again and again," said the children's nursery worker.
Sally has seen Les Mis all over the country as well as in New York and Stockholm but has recently been concentrating of her efforts on the London show and travels up once or twice a month.


text:
The Edison Innovation R&D Fund will provide funding to New Jersey technology companies for proof-of-concept research and development activities and ancillary activities necessary to commercialize the identified technology. Companies are encouraged to partner with a New Jersey PhD granting university or with a company or institution with a primary business location in New Jersey. Please note that NJCST does not require a fee to process this application.
Supplemental financing will be available through the New Jersey Economic Development Authority (NJEDA) for non-project specific costs not covered by the grant. Companies that are awarded the Edison Innovation R&D Fund can apply for and receive up to 20% of the approved NJCST grant, not to exceed $100,000, from the NJEDA in equity-like financing for non-R&D related costs. Terms for this supplemental funding are non-negotiable
- To grow successful technology businesses in New Jersey
- To grow jobs in New Jersey
- To promote collaboration between New Jersey technology companies and New Jersey research universities, companies or institutions
- To provide early-stage financing and commercialization support for New Jersey technology companies
Applications are not being accepted at this time
The Commission on Science and Technology will award grants to New Jersey Companies in the amounts of $100,000 to $500,000. The Edison Innovation R&D Fund will provide grants on a competitive basis.
Companies are encouraged to partner with any New Jersey PhD granting universities or with any company or institution with primary business location in New Jersey.
Lead Company eligibility
- Organized as a C Corp or an LLC
- Principal place of business in New Jersey
- 75% of employees live in New Jersey
- 75% of employees work in New Jersey
- Minimum of one full time employees at the company with applicable industry experience
- Total revenue of this company and all its subsidiaries is less than $10 million
- The applicant's primary business is the provision of a scientific process, product or service and the applicant owns, has filed for, or has a license to use protected, proprietary intellectual property.
- Company may not be a home or university based operation
Partner Organization Eligibility
- All New Jersey universities
Companies or institutions with primary business location in New Jersey
Matching Fund Requirements
Source of matching funds must be demonstrated and may not be other state funding sources
Applicant Company – must contribute cash at a minimum of 50% of CST funds
Partner University – must contribute in-kind or cash at a minimum of 20% of CST funds
Partner Company or Institution - must contribute cash at a minimum of 20% of CST funds


text:
FDA Explores Impact of Arsenic in Rice
In an FDA laboratory, chemist Patrick Gray, Ph.D., prepares rice-based food samples for an analysis that will determine if arsenic is present and, if so, how much. Get photos on Flickr.
What Should Consumers Do?
- Eat a well-balanced diet. All consumers, including pregnant women, infants and children, are encouraged to eat a well-balanced diet for good nutrition and to minimize the negative health effects that could come from eating an excess of any one food.
- Vary your grains. Like rice, other grains—such as wheat, barley and oats—are nutritious and can be used to help vary a consumer's diet.
- Consider alternatives for an infant's first solid food. Many infants are fed rice cereal as their first solid food. According to the American Academy of Pediatrics, there is no medical evidence that rice cereal has any advantage over other grains as a first solid food, and infants would likely benefit from eating a variety of grain cereals.
On this page:
The Food and Drug Administration (FDA) has taken a major step towards learning whether levels of arsenic in rice and rice products pose a risk to public health.
The agency has collected a total of more than 1,300 samples of rice and rice products and has tested them for both total arsenic and inorganic arsenic, the more toxic form. FDA scientists have determined that the levels of inorganic arsenic found in the samples are too low to cause immediate health damage.
In the rice grains, the average levels of inorganic arsenic ranged from 2.6 to 7.2 micrograms per serving, with instant rice at the low end of the range and brown rice at the high end. In rice products, the average levels of inorganic arsenic ranged from 0.1 to 6.6 micrograms per serving, with infant formula at the low end of the range and rice pasta at the high end. (A microgram is one-millionth of a gram; serving sizes varied with the product types.)
But what about the long-term impact? After all, rice is a food that people eat over the course of a lifetime.
The next step for FDA will be to conduct a comprehensive risk assessment, explains Suzanne C. Fitzpatrick, Ph.D., the senior advisor for toxicology in FDA's Center for Food Safety and Applied Nutrition (CFSAN). This analysis of the health risk associated with eating rice and rice products will be the foundation of future FDA actions.
"These are the next steps. To look at exposure levels, to analyze the risk, and determine how to minimize that risk for the overall safety of consumers, including vulnerable groups like children and pregnant women," says Fitzpatrick.
"We must take one step at a time and stay true to our methodological approach," says Michael R. Taylor, J.D., deputy commissioner for foods and veterinary medicine. "We can't get ahead of the science."
Why Rice?
"One of the things we need to emphasize is that arsenic is a naturally occurring contaminant, and because it's in soil and water, it's going to get into food," says Fitzpatrick. "It's not something that we can just pull off the market."
Arsenic is a chemical element distributed in the Earth's crust. Human activities such as fuel burning, mining and the use of arsenic compounds in pesticides have also added arsenic to the environment. But Fitzpatrick says that even if you stripped all human contributions, there would still be arsenic in food.
And rice is particularly vulnerable. "Rice is grown in water and takes in arsenic. You're going to see greater levels in rice than in other foods," she says.
FDA has been monitoring arsenic levels in foods for more than 20 years, but Fitzpatrick says there have been advances in testing that allow FDA to get much more detailed information.
The Story So Far
FDA consumer safety officers collected samples from retail outlets across the country. In addition to rice itself, these samples cover most types of rice-based foods in the American diet, including cereals, cakes, beverages, snack bars and infant and toddler foods.
These samples were then analyzed in FDA labs, in addition to some labs contracted by the agency to do this work. Fitzpatrick says the laboratory workers were required to undergo training in new chemical testing called "speciation." This testing enables the labs to look beyond just organic vs. inorganic to all the different species of arsenic present in the samples.
"It's a very complicated process and it involves a lot of people," Fitzpatrick says. "We're working very hard to get the best possible scientific answers."
Meanwhile, FDA was studying arsenic in other ways. Researchers examined studies of populations exposed to high levels of arsenic in such countries as Chile, Taiwan and Bangladesh. They looked at rates of cancer and diseases such as diabetes and cardiovascular illnesses.
The researchers had to consider how the data about these highly exposed cultures would apply to American consumers.
What's Next?
Next is the risk assessment. All of this information will now be considered by FDA risk managers, Fitzpatrick says. These experts will look at the hazards that arsenic presents in rice products and the degrees to which people are exposed.
The risk assessment teams will also consider if certain segments of the population are more vulnerable because of their lifestyle (such as ethnic groups that eat a lot of rice) or life stage (pregnant women and children).
They will then assess the public health risk from arsenic in rice.
The risk assessment will take a number of months to complete. After an expert review, the assessment will be available for public comment. "This is an important issue for us," say Fitzpatrick. "Consumers need the best information that we can get them."
FDA is working with federal partners—including the U.S. Department of Agriculture, the Environmental Protection Agency, the National Institute of Environmental Health Sciences, and the Centers for Disease Control and Prevention—as well as with industry scientists, consumer groups and others to further study the issue of arsenic in rice and evaluate ways to reduce exposure, such as through changes in growing or manufacturing practices.
And FDA is conducting additional sampling to broaden its data on the levels of arsenic in all infant and toddler products.
This article appears on FDA's Consumer Update page, which features the latest on all FDA-regulated products.
Sept. 6, 2013


text:
Lacas Ground Coffee Products:
Lacas Coffee Tiramisu Ground CoffeeLacas Coffee Tiramisu Ground Coffee 12oz Bag allow you to make mug after mug of decadent tiramisu flavored coffee from Lacas Ground Coffee. Learn More$6.9912 oz bagQty.
Coffee For Less carries a wide variety of superior Lacas Ground Coffee and Lacas Coffee alongside our imported gourmet coffee varieties, Kcup coffee, coffee pod refills, and residential or office coffee machines. Ground Coffee like Lacas Ground Coffee are delivered alongside your standard coffee, tea, or single serve K-Cup refills when you place your order at once, ensuring your home, office, or restaurant beverage service is stocked with Lacas Ground Coffee and Lacas Coffee whenever you are thirsty or need a little pick me up cup of coffee or tea.


text:
- Home
- News
- Sports
- Opinion
- Obituaries
- Features
- Special Sections
- Classifieds
- Public Notices
HEBRON ESTATES - North Bullitt Lady Eagle head coach Amber Courtney was well aware that with a team with no seniors and only one junior, that there would be nights where her team would learn tough, but ultimately important, lessons.
Friday against Bullitt East, the state's 23rd ranked team, was on of those nights.
The Lady Chargers were bigger, stronger, taller and more experienced as they rolled to a 66-34 victory that was not as close as the final score would indicate. Bullitt East had a 40-point advantage early in the fourth quarter.
If you currently subscribe or have subscribed in the past to the The Pioneer News, then simply find your account number on your mailing label and enter it below.
Click the question mark below to see where your account ID appears on your mailing label.
If you are new to the award winning The Pioneer News and wish to get a subscription or simply gain access to our online content then please enter your ZIP code below and continue to setup your account.
|ZIP Code:


text:
KeithBC wrote:Hi, folks! Nice place you have here. It's good to see some familiar faces.
Om mani padme hum
KeithBC wrote:Thanks.
As a Mahayanist, I probably won't have a lot to say here. However, I strongly believe that the Mahayana teachings really only make sense within the context of the Theravada teachings, so I like to stay in touch with Theravada sources.
Users browsing this forum: No registered users and 22 guests


text:
Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx
Recruitment status was: Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells of the mouth or oropharynx. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not known whether giving interleukin-2 with surgery and radiation therapy is more effective than surgery and radiation therapy alone.
PURPOSE: This randomized phase III trial is studying surgery and radiation therapy alone to see how well they work compared to surgery, radiation therapy, and interleukin-2 in treating patients with cancer of the mouth or oropharynx.
|Head and Neck Cancer
|Biological: aldesleukin Procedure: adjuvant therapy Procedure: conventional surgery Procedure: neoadjuvant therapy Radiation: radiation therapy
|Phase 3
|Study Type:
|Study Design:
|Allocation: Randomized
Primary Purpose: Treatment
|Official Title:
|Multicentre Randomised Trial of Inductive and Adjuvant Perilymphatically Injected Proleukin (rlL-2) in The Treatment of Operable Primary Squamous Cell Carcinoma of The Oral Cavity and Oropharynx
- Disease-free survival at 3 and 5 years
- Recurrence/metastasis rate at 3 and 5 years
- Response rate
- Local and systemic effects of treatment
|Estimated Enrollment:
|Study Start Date:
|September 1992
- Compare the disease-free and overall survival in patients with previously untreated squamous cell carcinoma of the oral cavity or oropharynx treated with resection with or without and neoadjuvant and adjuvant perilymphatic interleukin-2 (IL-2) and radiotherapy.
- Compare the response rate in patients treated with these regimens.
- Determine the local and systemic effects of locoregional IL-2 on host-tumor interaction and immune properties in these patients.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center and tumor stage (T2, N0-2 vs T2, N3 or T3-4, N0-3). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients undergo induction comprising interleukin-2 (IL-2) via perilymphatic injections to the ipsilateral myelohyoid muscle and insertion of the sternocleidomastoid muscle on days 1-5 and 8-12. Within 10 days after the last IL-2 injection, patients undergo en bloc resection of the primary tumor and corresponding lymphatic drainage area and pre-study margins. Beginning within 4 weeks after surgery, patients with T2, N0-3 disease but with pathohistological evidence of node invasion or capsular rupture of node metastasis or T3-4, N0-3 disease undergo adjuvant radiotherapy 5 days a week for 4.5-6.5 weeks. Beginning within 4 weeks after surgery or radiotherapy (if applicable), patients receive adjuvant IL-2 via perilymphatic injections to the contralateral myelohyoid muscle and insertion of the sternocleidomastoid muscle on days 1-5. Adjuvant IL-2 continues monthly for at least 1 year in the absence of disease progression.
- Arm II: Patients undergo resection and radiotherapy (if eligible) as in arm I. Patients are followed monthly for 1 year and then every 2 months for 2 years.
PROJECTED ACCRUAL: A total of 260 patients (130 per treatment arm) will be accrued for this study.
|Ages Eligible for Study:
|up to 75 Years (Child, Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Histologically proven squamous cell carcinoma of the oral cavity or oropharynx
- Operable, primary, unilateral, stage T2-4, N0-3, M0 disease
- No high probability of bilateral lymphatic spread (requirement for bilateral neck dissection)
No tumor involvement of the following sites:
- Pterygopalatine fossa
- Carotid artery
- Maxillary sinus
- Facial skin
- Anterior floor of the mouth
- Base of the tongue infiltrating more than 1 cm
- Measurable or evaluable disease by physical exam and/or noninvasive imaging
- 75 and under
Performance status:
- Karnofsky 70-100%
Life expectancy:
- More than 3 months
- WBC at least 4,000/mm3
- Platelet count at least 60,000/mm3
- Hematocrit at least 30%
- Bilirubin normal
- Hepatitis B surface antigen negative
- Creatinine normal
- No congestive heart failure
- No uncontrolled hypertension
- No coronary artery disease
- No serious arrhythmia
- No evidence of prior myocardial infarction on ECG (stress test required if in doubt)
- HIV negative
- No autoimmune disease
- No contraindications to pressor agents
- No serious infection requiring antibiotics
- No other concurrent primary malignancy
- Not pregnant or nursing
Biologic therapy:
- No prior or other concurrent immunotherapy
- No prior or concurrent chemotherapy
Endocrine therapy:
- No prior or concurrent hormonal therapy
- No concurrent corticosteroids
- No prior radiotherapy
- See Disease Characteristics
- No prior major organ allografts
- No other prior therapy
- No other concurrent investigational drugs, agents, or devices
- No concurrent nonsteroidal antiinflammatory drugs, ranitidine, cimetidine, or coumarin
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002702
|Universita Degli Studi di Bari
|Bari, Italy, 70124
|Contact: G. Cervellera, MD 39-080-5478-660
|Cattedra di Oncologia Medica - Universita degli Studi di Cagliari
|Cagliari, Italy, 09042
|Contact: P. Puxeddu, MD 39-070-5109-6253
|Universita di Ferrara
|Ferrara, Italy, 44100
|Contact: C. Calearo, MD 39-0532-209-296 email@example.com
|Universita Degli Studi di Florence - Policlinico di Careggi
|Florence, Italy, 50134
|Contact: O. Fini-Storchi, MD 39-55-411739
|Universita di Torino
|Turin, Italy, 10126
|Contact: G. Valente, MD 39-011-670-5955
|Azienda Sanitaria Ospedaliera Ordine Mauriziano
|Turin, Italy, 10128
|Contact: G. Forni, MD 39-11-508-1111
|Ospedale San Bortolo
|Vicenza, Italy, 36100
|Contact: C. Curioni, MD 39-444-993-906
|Study Chair:
|Giorgio Cortesina, MD
|Universita Degli Studi di Turin
|ClinicalTrials.gov Identifier:
|NCT00002702 History of Changes
|Other Study ID Numbers:
|Study First Received:
|November 1, 1999
|Last Updated:
|August 23, 2013
Keywords provided by National Cancer Institute (NCI):
stage II squamous cell carcinoma of the lip and oral cavity
stage III squamous cell carcinoma of the lip and oral cavity
stage IV squamous cell carcinoma of the lip and oral cavity
stage II squamous cell carcinoma of the oropharynx
stage III squamous cell carcinoma of the oropharynx
stage IV squamous cell carcinoma of the oropharynx
tongue cancer
Additional relevant MeSH terms:
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Neoplasms by Site
Antineoplastic Agents
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
ClinicalTrials.gov processed this record on September 21, 2017


text:
WaterLinks Forum 2014 will focus on urban water insecurity and wastewater efficiency in Asia and the Pacific through the lenses of climate change, disaster preparedness and water scarcity. Technical presentations will take place on water loss reduction, wastewater management and reuse, water quality monitoring and management, and climate change resilience. The Forum will also include a partnership matchmaking and networking session, and an innovation and knowledge fair. The Asian Development Bank (ADB) supports WaterLinks through the Water Operators Partnerships (WOPs) Program. WaterLinks is organizing the Forum with support from ADB, the International Water Association (IWA), the US Agency for International Development (USAID) and the Global Water Operators' Partnerships Alliance.
dates: 11-13 August 2014
location: Manila, Philippines
contact: Anna Romelyn Almario
phone: +632 632 4444
fax: +632 636 2198
www: http://www.adb.org/news/events/waterlinks-forum-2014?ref=sectors/water/events


text:
Bike Week rides into Dodger Stadium Saturday
LOS ANGELES -- The road to Dodger Stadium will be full of cyclists on Saturday afternoon.
More than 100 participants will ride from Union Station to the ballpark before Saturday's game against the Marlins, where they will be greeted by Hall of Fame manager Tommy Lasorda. Riders will tour the stadium once they arrive and attend the game.
The event is part of Bike Week Los Angeles and is organized by the Dodgers, C.I.C.L.E., the Eastside Bike Club and Metro.
Fans can purchase tickets to participate in this event by visiting www.dodgers.com/metro.
Ken Gurnick is a reporter and Austin Laymance is an associate reporter for MLB.com. This story was not subject to the approval of Major League Baseball or its clubs.


text:
15 U.S. Code § 80a–4 - Classification of investment companies
prev | next
For the purposes of this subchapter, investment companies are divided into three principal classes, defined as follows:
(1) "Face-amount certificate company" means an investment company which is engaged or proposes to engage in the business of issuing face-amount certificates of the installment type, or which has been engaged in such business and has any such certificate outstanding.
(2) "Unit investment trust" means an investment company which
(A) is organized under a trust indenture, contract of custodianship or agency, or similar instrument,
(C) issues only redeemable securities, each of which represents an undivided interest in a unit of specified securities; but does not include a voting trust.
Source(Aug. 22, 1940, ch. 686, title I, § 4,54 Stat. 799.)
Transfer of Functions
For transfer of functions of Securities and Exchange Commission, with certain exceptions, to Chairman of such Commission, see Reorg. Plan No. 10 of 1950, §§ 1, 2, eff. May 24, 1950, 15 F.R. 3175, 64 Stat. 1265, set out under section 78d of this title.
LII has no control over and does not endorse any external Internet site that contains links to or references LII.


text:
With funding from the National Human Genome Research Institute, joint Principal Investigators Robert C. Green, MD, MPH of Brigham and Women's Hospital and Harvard Medical School and J. Scott Roberts, PhD of the University of Michigan School of Public Health teamed up with leading personal genome testing companies 23andMe and Pathway Genomics Corporation to launch PGen.
"The goal is to produce results that can be translated into recommendations to guide policy and practice in this rapidly emerging area," said Green.
The group leading PGen will survey consumers of personal genome testing to identify their motivations, expectations, and attitudes, as well as their responses to learning their genetic disease risk, carrier status, and drug response results.
PGen is set to launch with the distribution of surveys to new consumers of personal genomic services. PGen will enroll 1,000 participants in all: 500 customers of Pathway Genomics and 500 customers of 23andMe. Researchers will then be able to compare survey responses to the genetic results, providing unique insight into the risks and benefits of personal genomic services.
"There has been considerable speculation, but not a lot of data, to inform the debate about the possible benefits and harms of personal genomics services," says Roberts. "We hope that our study will help to bridge this evidence gap."
To carry out the research, Green and Roberts assembled an interdisciplinary team of experts with backgrounds in medicine, genetics, genetic testing policy and practice, health communication, genetic counseling, health psychology, health law, bioethics and web survey design, many of whom have worked together on related prior research.
At the end of the project, the PGen team expects to understand: (1) who seeks personal genomic testing and why; (2) the impact of test results on psychological response, risk perception and comprehension, and personal utility; and (3) what consumers do with their genetic information (i.e. make health behavior or insurance changes, seek further information or communicate with family and health care providers).
About Pathway Genomics
Pathway Genomics owns and operates an on-site genetic testing laboratory that is accredited by the College of American Pathologists (CAP), accredited in accordance with the U.S. Health and Human Services' Clinical Laboratory Improvement Amendments (CLIA) of 1988, and licensed by the state of California. The company uses customized and scientifically validated genetic testing technologies to generate personalized genetic reports, which address a variety of genetic issues, including an individual's carrier status for recessive genetic conditions, food metabolism and exercise response, prescription drug response, and propensity to develop certain diseases, such as heart disease, type 2 diabetes, and cancer. For more information about Pathway Genomics, visit www.pathway.com.
Pathway Genomics
Zak Pugh
(858) 217-4358


text:
Pet column: Service, therapy and working animals defined and honored
September 24, 2012
The 2012 September National Service Dog recognition month salutes in particular guide dogs and military working dogs. Established by celebrity Dick Van Patton as National Guide Dog Month, the theme was broadened to reflect changes in current definitions and concerns related to the category of helping animals. In federal law, as of March 2011, the Americans with Disabilities Act was revised to change "service animal" to "service dog," allowing for limited application to miniature guide horses. Currently a Congressional bill is in committee for the change of military dog classification as "equipment" to "canine members of the Armed Forces," allowing for adoption upon retirement, valor decoration and other benefits of service.
The previous, loose definition of service animal under the ADA act resulted in fraud, physical harm caused by untrained and inappropriately designated "service animals" and public accommodation denial and/or embarrassment for disabled persons with a bona fide service animal. In 2008, it was reported that the manager of a Seattle Trader Joe's market fielded 300 incidents of patrons declaring right to access with self-declared service animals. The manager incurred insult and outrage when he legally questioned the status, allowed access, and then had to referee incidents with patrons caused by the animal while in the store. A 2009 San Francisco Gate article revealed the consequences to drivers and passengers on public transportation when riders with exotic animals such as snakes and aggressive dogs boarded buses declaring their animal companions were "service animals." Many states have developed their own ordinances and penalties for abuse of the public accommodation privilege intended for disabled persons.
No one is completely satisfied with the recently revised federal regulations. One concern is the "invisible disability" not addressed in legislation. Groups are lobbying for wider recognition of the need for including a mental health animal service category. Veterans are appealing to allow benefits covering service dogs in Post Traumatic Syndrome Disorder therapy. The Michigan State University College of Law published a paper with five recommendations for improving the overall situation. Those include standardized training and credible certification for all service animals and trainers, as well as enforceable, definitive national regulations adopted by all states. Also at issue are pet owners who take advantage of the readily available vests, badges, gear and "certificates" available on the Internet, then effectively deny access to bona fide working animals. The most common violations are to claim a free open space in the passenger cabin of an airline or to gain access to public health regulated establishments such as restaurants. A category of "comfort" pets has displaced guide, hearing and signal animals by stealing the limited accommodations available. Standardized identification as required outside of the United States would help matters.
The category of "therapy" animal has become fuzzy through generalized use of the label. Therapy animals are not necessarily service animals. Certified therapy animals are usually owned by institutions, handled by specially trained staff, and are not the casual visiting pets seen in most convalescent facilities. Therapy animals are used in measured, goal directed medical applications. Search and rescue is another nonservice animal category covered by limited law for saving lives in disasters and emergencies. Like therapy dogs, they have people contact but do not provide ongoing support for an individual disabled person. Credentialed therapy animals and certified search-and-rescue dogs are given access to specific public accommodation by law to enable travel to facilities and incidents.-
It is a cruel irony that while science proves increasing benefits of the human-animal bond, thoughtless humans deny others access for healing and independence with trained service, therapy and working animals. These loyal, self-sacrificing animals are not pets except when off duty. They are guide, hearing-, signal- and function-trained service workers. Another goal of this year's recognition of service dogs is the private funding of a National Monument to honor Military Working Dogs, elevating animals to an unprecedented status. God bless them, every one.
– Provided by the Lake Tahoe Humane Society and Society for the Prevention of Cruelty to Animals to help "Keep Tahoe Kind". Dawn Armstrong is the executive director.


text:
If this thread needs to be moved, please do so! I thought this might be the closest sub-forum for my question.
I'd like to stay in Asia (looking at perhaps Thailand or Sri Lanka) for about three months for study and meditation retreat next year. However, as a female my choices are more limited by both availability and safety concerns.
Does anyone have a temple, nunnery or retreat center they could recommend for a lay woman to study at? I have no wish to ordain at this time, but only to go deeper into my practice and volunteer if given the opportunity. The reason for staying in Asia is that I also wish to live in a Buddhist country for a period of time to better understand the place of Dhamma in everyday life.


text:
Pacers are going to have to box out and rebound Friday. Kings are a good rebounding team with Cousins, Dalembert and Thompson. Offensive boards killed the Bucks tonight, along with Beno and Marcus T
'); var yuipath = 'clientscript/yui'; var yuicombopath = ''; var remoteyui = false; } else // Load Rest of YUI remotely (where possible) { var yuipath = 'http://yui.yahooapis.com/2.9.0/build'; var yuicombopath = 'http://yui.yahooapis.com/combo'; var remoteyui = true; if (!yuicombopath) { document.write('
Pacers are going to have to box out and rebound Friday. Kings are a good rebounding team with Cousins, Dalembert and Thompson. Offensive boards killed the Bucks tonight, along with Beno and Marcus T
I will be there. I love the Pepsi can promotion where you can get club level seats for $20!!
Yep its one of those games that won't be televised like the Suns game from last month.
We are in the first playoff push in years and they are not showimg tje game on tv....
If the Pacers take care of business tomorrow, they SHOULD be looking at a 4 game lead with 9 games to play over the Bobcats as they play at Boston.
They'll also either be looking at a 4 game lead over the Bucks, or moving 2.5 back behind the Knicks with a win b/c the Bucks play at the Knicks.
Should be a pretty big win in terms of playoff positioning if the Pacers can beat the Kings tomorrow
I think they can change the TV broadcast though, I'm not sure about FSIND but we were scheduled for ESPN against the Pistons on 3/20/11. But now it's only on NBA LP. But I could be wrong about contracting or something with FS IND.
Pacers/Pistons is 3/30/11 and it's still on ESPN as of now according to Pacers.com
My wife and I (and the gnome) are in from Washington state - will be behind the p's bench. What should we do to get a few more autographs on the gnome?
I anticipate an adventure in parking tomorrow.
How early can we park at the one connected to the field house. Planned on going in early afternoon to walk around down town and leave the vehicle there.
Wow that deserves it's own thread!
I'll be there. I just counted homes games this season and my 80th home game in a row was last game. Reminds me of BPump forgetting his 50th game recently.
So mad. I missed the awesome Pacers PD Party I was planning on! Pacemates, Pacers Toast, Pacers Coffee, Paul George... maybe next season.
Yep, completely spaced 50. At least it was a win.
Just wait until you get to 100 next season. Talk about a party.
I'm currently at work and what the **** is wrong with people in this city seriously.
What more do they want?
Friday night, season winding down and we're rolling into the playoffs and theres thousands of tickets available.
I guess you cant be anymore competitive to see your team do well than the Indy fans.
Wait it out and the attendance will rise.
People will hop off the Colts bandwagon in the near future and they'll probably be last in attendance in the NFL and we'll be getting their bandwagoners.
In 49 states it's just basketball, but this is Indiana!
why the hell is this not on TV??
Admittedly I'm Indy born and raise so it's perhaps easier for me to say, being used to the city, but I've never felt threatened walking anywhere downtown to anyone concerned about safety. There might be an occasional panhandler or homeless person or whatever, but I doubt there are many cities more safe to walk around than Indy. At least if you stay downtown and don't venture further out toward the East or West sides.
im sitting here in a ****ing sea of green like usual
In 49 states it's just basketball, but this is Indiana!
What channel is this on?
i have no issue with walking from the fieldhouse to my car
theres a bunch of light and guards and other people
In 49 states it's just basketball, but this is Indiana!
I walk through the dark streets of downtown Cincinnati to get to Reds games. That place makes Indianapolis look like a resort. I have always felt pretty safe in Indy.
"The greatest thing you know Comes not from above but below" Danzig
comment timing fail
Bet you all wish you hadn't attended now.
In 49 states it's just basketball, but this is Indiana!


text:
- Home
- News
- Sports
- Opinion
- Obituaries
- Features
- Special Sections
- Classifieds
- Public Notices
Calling all citizens - Now is the time to get your flu shot, if you haven't already. The Bullitt County Health Department would like to remind people who have not yet been vaccinated that the time to get a flu vaccine is now and continues into winter through January or later, when the influenza season typically peaks. BCHD encourages all people to get a seasonal flu shot for their health and for the protection of those around you. This year's vaccine includes protection against H1N1.
If you currently subscribe or have subscribed in the past to the The Pioneer News, then simply find your account number on your mailing label and enter it below.
Click the question mark below to see where your account ID appears on your mailing label.
If you are new to the award winning The Pioneer News and wish to get a subscription or simply gain access to our online content then please enter your ZIP code below and continue to setup your account.
|ZIP Code:


text:
Ukiah Daily Journal
Son beaten in Fort Bragg domestic fight
A 56-year-old Fort Bragg man was arrested Monday after he allegedly beat his son, when the young man tried to stop him from attacking his mother, according to the Mendocino County Sheriff's Office.
The Sheriff's Office responded to a report at 5:30 p.m. Nov. 12 about an assault at a home in the 21000 block of John Hyman Road in Fort Bragg, where deputies found Matthew Jones, 18, with visible injuries. He declined emergency medical attention, according to the MCSO.
The young man explained that his father, Mark Jones, was attacking his mother and he had intervened. The father allegedly turned his attention on his son, punching and kicking him about the head and upper body, according to the MCSO.
The mother told deputies her husband, Mark Jones, had attacked her, causing pain, and also declined medical help.
Mark Jones was arrested on suspicion of assault with a deadly weapon and domestic battery, and booked at the Mendocino County Jail under $30,000 bail.
Southern California man arrested with 'shrooms
A 24-year-old man from Southern California was arrested for allegedly having hallucinogenic mushrooms after the smell of marijuana led to a vehicle search in the town of Mendocino late Monday night, according to the Mendocino County Sheriff's Office.
Deputies patrolling the town at about 11:30 p.m. Nov. 12 spotted a black Dodge Neon parked in a dirt lot behind the Presbyterian Church on Main Street and spoke to the three people inside. The deputies smelled marijuana coming from the vehicle and searched it, finding that one of the passengers, Brenden Shine, 24, a transient from Morro Bay, had 257 grams of psilocybin mushrooms, according to the MCSO.
Shine allegedly admitted possessing them, and said he intended to share the mushrooms with people at parties because he "likes to have fun," according to the MCSO.
Shine was arrested on suspicion of possessing psilocybin mushrooms for sale and booked at the Mendocino County Jail under $25,000 bail.


text:
- Home
- News
- Sports
- Opinion
- Obituaries
- Features
- Special Sections
- Classifieds
- Public Notices
On what was Day 14 of Barack Obama's term as president, Chiefland's Robert and Rutha Scott were as excited as if it were Jan. 20 all over again.
If you currently subscribe or have subscribed in the past to the Chiefland Citizen, then simply find your account number on your mailing label and enter it below.
Click the question mark below to see where your account ID appears on your mailing label.
If you are new to the award winning Chiefland Citizen and wish to get a subscription or simply gain access to our online content then please enter your ZIP code below and continue to setup your account.
|ZIP Code: